Major surgery increases serum levels of vascular endothelial growth factor only temporarily

Bondestam, Jonas; Salvén, Petri; Jääskela-Saari, Hilkka; Ikonen, Tuija; Lepäntalo, Mauri; Mattila, S; Joensuu, Heikki

doi:10.1016/s0002-9610(99)00253-6

Cited by 34 publications

(18 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Concomitantly, levels of angiostatin and endostatin in urine and plasma, respectively, dropped. Moreover, others demonstrated that serum VEGF was markedly elevated after surgery, especially during the first days after resection [81][82][83][84]. Taken together, these findings suggest that surgery may cause a switch in the angiogenic balance.…”

Section: Angiogenesis Inhibitors and Surgerymentioning

confidence: 83%

Angiogenesis Inhibitors: Perspectives for Medical, Surgical and Radiation Oncology

Verhoef¹,

Wilt²,

Verheul³

2006

CPD

View full text Add to dashboard Cite

In the past decade, many angiogenesis inhibitors have been developed for clinical use in oncology. Surgeons, radiotherapists as well as medical oncologists have been investigating with much effort and enthusiasm the translation of these agents from the preclinical setting into treatment strategies of patients. Recently, for the first time in history, the angiogenesis inhibitor bevacizumab (avastin), a humanized anti-vascular endothelial growth factor (VEGF) antibody, showed a survival benefit of 4.7 months in a phase III clinical trial in patients with advanced colorectal cancer when this agent was given in combination with chemotherapy. At the annual meeting of the American Association of Clinical Oncology 2005, similar results of bevacizumab in lung, breast and ovarian cancer clinical trials have been shown. These landmark studies proofed for the first time in the clinical setting that Dr. Folkman back in 1971 was right by proposing: "in order to stop tumor growth, one should attack its blood supply". Nowadays it seems trivial to propose such a hypothesis, at that time it was a very provocative hypothesis and it took more than 30 years to proof this hypothesis in the clinic. Although one may be excited about this major finding, there is no time to relax. The survival benefit of bevacizumab is only about 4 months. Therefore more potent antiangiogenic agents and more active treatment strategies are urgently warranted. Newer angiogenesis inhibitors that are currently in preclinical or early clinical development have shown in preclinical experiments improved antitumor activities. In addition, combinations of biological agents that interfere in multiple biological pathways in cancer growth including chemotherapy, are of major clinical interest as well. The multimodality approach in which surgeons, radiotherapists and medical oncologists collaborate needs to be explored as well. In a variety of cancer types, like breast colon and lung cancer, these specialists should design multimodality strategies based on current standard treatment in which they incorporate angiogenesis inhibitors in the right time frame of surgery and radiotherapy. In this review we will bring you up to date on the clinical development of angiogenesis inhibitors and we will summarize the multimodality strategies that are under development.

show abstract

Section: Angiogenesis Inhibitors and Surgerymentioning

confidence: 83%

Angiogenesis Inhibitors: Perspectives for Medical, Surgical and Radiation Oncology

Verhoef¹,

Wilt²,

Verheul³

2006

CPD

View full text Add to dashboard Cite

show abstract

“…Since 1993 Kim found blocking the expression of VEGF acting in blood vascular system could significantly inhibit the growth of tumor, an increasing number of researches showed that the level of VEGF reflexed the proliferation, migration and blood vessel construction of tumor endothelial cell and directly reflected the growth speed and metastasis of tumor (Bondestam et al, 2000). Shan et al (Shan et al, 2004) suggested that the positive expression rate of VEGF in esophageal cancer tissues was 70.9% and the expression of VEGF was associated with pathology classification, depth of invasion and lymphatic metastasis, which provide the theoretical foundation for the treatment of esophageal cancer by blocking the expression of VEGF.…”

Section: Discussionmentioning

confidence: 99%

Clinical Observation and Therapeutic Evaluation of Rh-endostatin Combined with DP Regimen in Treating Patients with Advanced Esophageal Cancer

Deng

Song²,

Li³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Objective: To observe the curative effects of rh-endostatin combined with DP regimen in treating patients with advanced esophageal cancer and analyze the correlation of CT perfusion (CTP) parameters and the expression of vascular endothelial growth factor (VEGF). Methods: Twenty patients with esophageal cancer confirmed pathologically were randomly divided into combined treatment (rh-endostatin+DP regimen) group and single chemotherapy group, 10 patients in each group, respectively. All patients were given conventional CT examination and CTP imaging for primary tumor. The level of VEGF, the size of tumor and CTP parameters (BF, BV, PS and MTT) before treatment and after 2 cycles of treatment were determined for the comparison and the correlation between CTP parameters and VEGF expression was analyzed. Results: the therapeutic effect of rh-endostatin+DP regimen group was superior to single chemotherapy group. VEGF level after treatment in rhendostatin +DP regimen group was obviously lower than single chemotherapy group (P<0.01). The expression of VEGF had positive correlation with BF and BV but negative correlation with MTT. Compared with treatment before for rh-endostatin +DP regimen group, BF, BV and PS decreased while MTT increased after treatment (P<0.05). However, there were no significant differences between treatment before and after treatment in single chemotherapy (P>0.05). Conclusions: Rh-endostatin can down-regulate the expression of VEGF in esophageal cancer, change the state of hypertransfusion and high permeability of tumor vessels and had the better curative effect and slighter adverse reactions when combined with chemotherapy.

show abstract

“…The effect of surgical intervention on VEGF levels has been examined, and major surgery for nonmalignant disease induced the highest transient VEGF increase on POD 1 [23]. Maniwa et al [24] also showed that pulmonary surgery induced VEGF elevation temporarily in patients with metastatic lung cancer.…”

Section: Discussionmentioning

confidence: 99%

Surgery for gastric cancer increases plasma levels of vascular endothelial growth factor and von Willebrand factor

et al. 2002

View full text Add to dashboard Cite

Background. Angiogenesis and hemostatic activation are important factors in tumor progression and metastasis. Because surgical intervention induces tissue hypoxia and hemostatic activation, we analyzed the effect of gastric surgery on the plasma concentrations of vascular endothelial growth factor (VEGF), soluble P-selectin (sP-selectin), and von Willebrand factor (vWf). Methods. Plasma VEGF, sP-selectin, and vWf concentrations were measured in 14 patients with gastric cancer before operation and on postoperative day 1 (POD 1). Correlations between disease stage and the effect of surgical intervention were analyzed. Results. The plasma concentrations of these three factors did not correlate with the disease stage. Plasma levels of sPselectin did not change after operation (before surgery, 87.6 ؎ 34.1 ng /ml; on POD 1, 101.1 ؎ 48.1 ng/ml; P ‫؍‬ 0.123). Plasma VEGF and vWf concentrations were significantly elevated on POD 1 (VEGF, 33.3 ؎ 20.5 pg /ml before surgery and 61.9 ؎ 35.6 pg /ml on POD 1; P ‫؍‬ 0.0013; vWf, 164 ؎ 31.1% before surgery and 211.1 ؎ 66.1% on POD 1; P ‫؍‬ 0.027). Conclusion. Because VEGF and vWf are involved in angiogenesis, tumor-platelet adhesion, and tumor-endothelial cell adhesion, surgical intervention could influence tumor growth and metastasis.

show abstract

Major surgery increases serum levels of vascular endothelial growth factor only temporarily

Cited by 34 publications

References 8 publications

Angiogenesis Inhibitors: Perspectives for Medical, Surgical and Radiation Oncology

Angiogenesis Inhibitors: Perspectives for Medical, Surgical and Radiation Oncology

Clinical Observation and Therapeutic Evaluation of Rh-endostatin Combined with DP Regimen in Treating Patients with Advanced Esophageal Cancer

Surgery for gastric cancer increases plasma levels of vascular endothelial growth factor and von Willebrand factor

Contact Info

Product

Resources

About